Pub. Date : 2020 May
PMID : 32642151
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. | apatinib | epidermal growth factor receptor | Homo sapiens |
| 2 | Background: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR). | apatinib | epidermal growth factor receptor | Homo sapiens |
| 3 | Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR. | apatinib | epidermal growth factor receptor | Homo sapiens |